

**Medivisor, Inc. (Other OTC: MVSR)**

Medivisor, Inc., founded in 2002 and headquartered in Huntington Station, New York, is a developer and provider of next-generation focus-driven technology-based marketing tools for the bioscience and pharmaceutical markets. The company provides medical information to healthcare professionals, primarily physicians, through its websites - www.statdose.com and www.medivisor.com, using inter-active, informational, video and graphic presentations. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective integrated marketing and creative communications campaigns for the benefit of its clients. Using an online marketing format containing concise professional presentation of pertinent information known as e-detailing, Medivisor's services complement pharmaceutical companies' existing marketing strategies enabling cost-effective, time-efficient on-demand interaction with physicians without impacting patient care or interfering with daily medical office operations. The company also focuses on offering website services to various industries seeking direct access to physicians, including providers of continuing medical education courses and sponsors of medical conferences and seminars. Finally, the company acts as a sales agent utilizing its expertise to distribute pharmaceutical and other health products domestically and internationally. The company has a profit-sharing relationship with Cura Pharmaceutical Co., Inc. regarding Mucotrol™, an FDA-approved oral gel wafer device for treatment of mouth sores related to chemotherapy, radiotherapy and irritation due to oral surgery, and Albumax, an easily-absorbed whey protein isolate formula increasing blood albumin levels for kidney disorder patients. It also has a revenue-sharing agreement with PanGenex Corporation for LIPIDEME™, a synergistic blend of ingredients designed to lower cholesterol. Additionally, the company is marketing Maximum Energy Shot, its four-calorie several-hour sustainable energy shot.

CURRENT PRICE: \$0.24  
52-WEEK RANGE: \$0.15 - \$1.65  
AVG DAILY VOLUME (90-DAY): 23,100  
OUTSTANDING SHARES: 13.8 million  
MARKET CAPITALIZATION: \$3.3 million  
TARGET PRICE: \$0.60

**INCOME STATEMENT HIGHLIGHTS**

REVENUE: \$809.8 thousand  
GROSS PROFIT: \$542.0 thousand  
EBITDA: (\$284.2 thousand)  
NET INCOME: (\$289.8 thousand)  
Diluted EPS: (\$0.04)

All income statement figures twelve months trailing as of December 31, 2007

**BALANCE SHEET HIGHLIGHTS**

CASH: \$2.3 thousand  
WORKING CAPITAL: (\$625.2 thousand)  
TOTAL ASSETS: \$209.2 thousand  
NET WORTH: (\$506.8 thousand)

All balance sheet figures as of December 31, 2007

**RECENT NEWS HEADLINES**

Thu, Sep 25

Medivisor announced today that Albumax has been approved by the California and the Pennsylvania State Medicaid Offices as an enteral product under code B4155, coming on the heels of previously received New York approval.

Wed, Sep 24

Medivisor has received a purchase order for Albumax from Critical Healthcare Solutions, Inc.

Mon, Sep 22

Medivisor announced it is in final negotiations with its first nationwide distributor for sales of Maximum Energy Shot, with the contemplated agreement calling for minimum orders of \$500,000 in an annually renewable contract.

**HEADQUARTERS**

**Medivisor, Inc.**  
326 Walt Whitman Road  
Huntington Station, NY 11746  
Phone: 631-549-7100 Fax: 631-549-7119  
Web Site: [www.medivisor.com](http://www.medivisor.com)  
Email: [dluzzi@medivisor.com](mailto:dluzzi@medivisor.com)



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. Readers should understand target price is not a prediction or forecast, but merely reflects possible returns to prior historical levels based on improved market conditions and eventual realization of company milestones and is therefore highly speculative. The featured company paid a consulting fee of \$2,500 to Alan Stone & Company LLC for preparation and distribution of this profile. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the [www.WallStreetResearch.org](http://www.WallStreetResearch.org) website.